Azithromycin Synergizes with Cationic Antimicrobial Peptides to Exert Bactericidal and Therapeutic Activity Against Highly Multidrug-Resistant Gram-Negative Bacterial Pathogens

EBioMedicine

Volumn 2, Issue 7, 2015, Pages 690-698

  Lin, Leo ^a   Nonejuie, Poochit ^b   Munguia, Jason ^a   Hollands, Andrew ^a   Olson, Joshua ^a   Dam, Quang ^a   Kumaraswamy, Monika ^f   Rivera, Heriberto ^c   Corriden, Ross ^a   Rohde, Manfred ^a   Hensler, Mary E ^a   Burkart, Michael D ^c   Pogliano, Joe ^b   Sakoulas, George ^a   Nizet, Victor ^a,d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Acinetobacter baumannii; Antibiotic resistance; Antimicrobial peptides; Azithromycin; Cathelicidin; Colistin; Klebsiella pneumoniae; LL 37; Macrolides; Pseudomonas aeruginosa

Indexed keywords

ANTIMICROBIAL CATIONIC PEPTIDE; AZITHROMYCIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; ERYTHROMYCIN; MACROLIDE; ANTIINFECTIVE AGENT; ANTIMICROBIAL PEPTIDE LL-37; CATHELICIDIN; CULTURE MEDIUM;

ACINETOBACTER BAUMANNII; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CELL MEMBRANE PERMEABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLUORESCENCE MICROSCOPY; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; HUMAN; INFLAMMATORY INFILTRATE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; C57BL MOUSE; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; MICROBIAL SENSITIVITY TEST; ULTRASTRUCTURE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; AZITHROMYCIN; CATHELICIDINS; CELL MEMBRANE PERMEABILITY; COLISTIN; CULTURE MEDIA; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; FEMALE; GRAM-NEGATIVE BACTERIA; HUMANS; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS;

EID: 84951574228     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.05.021     Document Type: Article

References (49)

1. Amsden G.W. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 2001, 18(Suppl. 1):S11-S15.
2. Appleman M.D., Belzberg H., Citron D.M., Heseltine P.N., Yellin A.E., Murray J., Berne T.V. In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob. Agents Chemother. 2000, 44:1035-1040.
3. Azithromycin Package Insert, SAGENT Pharmaceuticals Azithromycin for Injection 2013.
4. Barry A., Bryskier A., Traczewski M., Brown S. Preparation of stock solutions of macrolide and ketolide compounds for antimicrobial susceptibility tests. Clin. Microbiol. Infect. 2004, 10:78-83.
5. Baumann U., Fischer J.J., Gudowius P., Lingner M., Herrmann S., Tummler B., von der Hardt H. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2001, 29:7-11.
6. Beigelman A., Gunsten S., Mikols C.L., Vidavsky I., Cannon C.L., Brody S.L., Walter M.J. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest 2009, 136:498-506.
7. Biswas S., Brunel J.M., Dubus J.C., Reynaud-Gaubert M., Rolain J.M. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti-Infect. Ther. 2012, 10:917-934.
8. Braga P.C., Piatti G. Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells. Chemotherapy 1993, 39:432-437.
9. Buyck J.M., Plesiat P., Traore H., Vanderbist F., Tulkens P.M., Van Bambeke F. Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability. Clin. Infect. Dis. 2012, 55:534-542.
10. Cederlund A., Gudmundsson G.H., Agerberth B. Antimicrobial peptides important in innate immunity. FEBS J. 2011, 278:3942-3951.
11. Cegelski L., Marshall G.R., Eldridge G.R., Hultgren S.J. The biology and future prospects of antivirulence therapies. Nat. Rev. Microbiol. 2008, 6:17-27.
12. Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States 2013, (2013).
13. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing. 19th Informational Supplement 2008, M100-S119. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
14. Diene S.M., Rolain J.M. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas, and Acinetobacter species. Clin. Microbiol. Infect. 2014, 20:831-838.
15. Dorschner R.A., Lopez-Garcia B., Peschel A., Kraus D., Morikawa K., Nizet V., Gallo R.L. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J. 2006, 20:35-42.
16. Fair R.J., Hensler M.E., Thienphrapa W., Dam Q.N., Nizet V., Tor Y. Selectively guanidinylated aminoglycosides as antibiotics. ChemMedChem 2012, 7:1237-1244.
17. Gallo R.L., Hooper L.V. Epithelial antimicrobial defence of the skin and intestine. Nat. Rev. Immunol. 2012, 12:503-516.
18. Gillis R.J., Iglewski B.H. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J. Clin. Microbiol. 2004, 42:5842-5845.
19. Girard A.E., Girard D., Retsema J.A. Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J. Antimicrob. Chemother. 1990, 25(Suppl. A):61-71.
20. Hancock R.E., Nijnik A., Philpott D.J. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 2012, 10:243-254.
21. Haste N.M., Hughes C.C., Tran D.N., Fenical W., Jensen P.R., Nizet V., Hensler M.E. Pharmacological properties of the marine natural product marinopyrrole A against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2011, 55:3305-3312.
22. Helander I.M., Mattila-Sandholm T. Fluorometric assessment of gram-negative bacterial permeabilization. J. Appl. Microbiol. 2000, 88:213-219.
23. Hicks L.A., Taylor T.H., Hunkler R.J. U.S. outpatient antibiotic prescribing, 2010. N. Engl. J. Med. 2013, 368:1461-1462.
24. Hoffmann N., Lee B., Hentzer M., Rasmussen T.B., Song Z., Johansen H.K., Givskov M., Hoiby N. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in CFTR (-/-) mice. Antimicrob. Agents Chemother. 2007, 51:3677-3687.
25. Imamura Y., Higashiyama Y., Tomono K., Izumikawa K., Yanagihara K., Ohno H., Miyazaki Y., Hirakata Y., Mizuta Y., Kadota J., et al. Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. 2005, 49:1377-1380.
26. Kadurugamuwa J.L., Sin L., Albert E., Yu J., Francis K., DeBoer M., Rubin M., Bellinger-Kawahara C., Parr T.R., Contag P.R. Direct continuous method for monitoring biofilm infection in a mouse model. Infect. Immun. 2003, 71:882-890.
27. Kannan K., Vazquez-Laslop N., Mankin A.S. Selective protein synthesis by ribosomes with a drug-obstructed exit tunnel. Cell 2012, 151:508-520.
28. Koike M., Iida K., Matsuo T. Electron microscopic studies on mode of action of polymyxin. J. Bacteriol. 1969, 97:448-452.
29. Leonard S.N. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model. PLoS One 2012, 7:e42103.
30. Matijasic M., Munic Kos V., Nujic K., Cuzic S., Padovan J., Kragol G., Alihodzic S., Mildner B., Verbanac D., Erakovic Haber V. Fluorescently labeled macrolides as a tool for monitoring cellular and tissue distribution of azithromycin. Pharmacol. Res. 2012, 66:332-342.
31. Mauldin P.D., Salgado C.D., Hansen I.S., Durup D.T., Bosso J.A. Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria. Antimicrob. Agents Chemother. 2010, 54:109-115.
32. Molinari G., Paglia P., Schito G.C. Inhibition of motility of Pseudomonas aeruginosa and Proteus mirabilis by subinhibitory concentrations of azithromycin. Eur. J. Clin. Microbiol. 1992, 11:469-471.
33. Molinari G., Guzman C.A., Pesce A., Schito G.C. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 1993, 31:681-688.
34. Nonejuie P., Burkart M., Pogliano K., Pogliano J. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:16169-16174.
35. Peleg A.Y., Hooper D.C. Hospital-acquired infections due to gram-negative bacteria. N. Engl. J. Med. 2010, 362:1804-1813.
36. Pruul H., McDonald P.J. Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. Antimicrob. Agents Chemother. 1992, 36:10-16.
37. Revelli D.A., Boylan J.A., Gherardini F.C. A non-invasive intratracheal inoculation method for the study of pulmonary melioidosis. Front. Cell. Infect. Microbiol. 2012, 2:164.
38. Sakoulas G., Bayer A.S., Pogliano J., Tsuji B.T., Yang S.J., Mishra N.N., Nizet V., Yeaman M.R., Moise P.A. Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 2012, 56:838-844.
39. Sakoulas G., Okumura C.Y., Thienphrapa W., Olson J., Nonejuie P., Dam Q., Dhand A., Pogliano J., Yeaman M.R., Hensler M.E., et al. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus. J. Mol. Med. 2014, 92:139-149.
40. Sato T. A modified method for lead staining of thin sections. J. Electron Microsc. (Tokyo) 1968, 17:158-159.
41. Sochacki K.A., Barns K.J., Bucki R., Weisshaar J.C. Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E77-E81.
42. Spapen H., Jacobs R., Van Gorp V., Troubleyn J., Honore P.M. Renal and neurological side effects of colistin in critically ill patients. Ann. Intensive Care 2011, 1:14.
43. Timurkaynak F., Can F., Azap O.K., Demirbilek M., Arslan H., Karaman S.O. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int. J. Antimicrob. Agents 2006, 27:224-228.
44. Vaara M., Siikanen O., Apajalahti J., Fox J., Frimodt-Moller N., He H., Poudyal A., Li J., Nation R.L., Vaara T. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 2010, 54:3341-3346.
45. World Health Organization Antimicrobial Resistance: Global Report on Surveillance 2014.
46. Yamada K., Yanagihara K., Kaku N., Harada Y., Migiyama Y., Nagaoka K., Morinaga Y., Nakamura S., Imamura Y., Miyazaki T., et al. Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2013, 57:3883-3888.
47. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur. J. Clin. Pharmacol. 2012, 68:479-503.
48. Zurawski D.V., Thompson M.G., McQueary C.N., Matalka M.N., Sahl J.W., Craft D.W., Rasko D.A. Genome sequences of four divergent multidrug-resistant Acinetobacter baumannii strains isolated from patients with sepsis or osteomyelitis. J. Bacteriol. 2012, 194:1619-1620.
49. Zusman D.R., Carbonell A., Haga J.Y. Nucleoid condensation and cell division in Escherichia coli MX74T2 ts52 after inhibition of protein synthesis. J. Bacteriol. 1973, 115:1167-1178.